What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Angiotensin-IV-derived synaptogenic compound · cognition research
Overview
Dihexa is a small, centrally-active compound derived from angiotensin IV and engineered at Washington State University to cross the blood-brain barrier — chemically it is N-hexanoyl-Tyr-Ile-(6)-aminohexanoic acid amide. It straddles the peptide/small-molecule boundary: the N-hexanoyl cap and aminohexanoic spacer remove most of the peptide character that would otherwise block membrane permeability. In laboratory work it is studied as a reported driver of new dendritic-spine and synapse formation, with a proposed mechanism running through the hepatocyte growth factor (HGF)/c-Met signaling system. PeptideXpo supplies dihexa as a lyophilized powder at ≥ 98% HPLC. Its lipophilic hexanoyl group makes it poorly water-soluble — research protocols typically dissolve it first in a small volume of DMSO before dilution into aqueous buffer, keeping the final co-solvent fraction low enough not to perturb the assay. Supplied in 10 mg fills as a research reference material only. As with any early-stage neurotrophic tool compound, its literature base is still developing and it is not approved for any clinical use.
Who buys this, and why
Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the literature is intranasal, these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the COA stage so the bioassay readout is not confounded by contamination unrelated to the test article.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
Dihexa's N-hexanoyl group makes it lipophilic and poorly soluble in plain water. The standard research approach is to prepare a concentrated stock in DMSO (or ethanol), then dilute into aqueous buffer immediately before use, keeping the final DMSO fraction low enough not to affect the biological readout. Prepare fresh working dilutions and store the concentrated stock frozen and desiccated.
Functionally it is treated as a small-molecule mimetic even though it is built from a modified peptide backbone. The N-terminal hexanoyl cap and aminohexanoic spacer replace the natural termini that make ordinary peptides membrane-impermeant — the design feature behind its reported CNS penetrance. That hybrid character is also why it is handled with small-molecule solubility methods (organic co-solvent) rather than the straight-aqueous reconstitution used for hydrophilic peptides.
